According to the World Health Organization (WHO), around 570,000 women died due to breast cancer in 2015. Moreover, according to the Centers for Disease Control and Prevention (CDC), around 236,968 Women Diagnosed with breast cancer among which around 41,211 women died in 2014. The data indicating a high prevalence of chronic diseases affects lifestyle of women day-by-day. Growing demand for early stage diagnosis of infection/diseases needs new rapid diagnostic tests and imaging system which is expected to fuel the growth of women’s health diagnostic test market in the near future.
Download PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/971
In 2017, Naugatuck Valley Women’s Health Specialists (NVWHS) decided to provide a free informational program for heart health with Boston Heart Diagnostics. Boston Heart diagnostics has anticipating treatment and diagnosis of cardiovascular diseases (CVD), which improves women’s heart health, as CVD is a leading disease in the U.S. This program is expected to create awareness of CVD related diseases among women and also help to improve lifestyle.
In 2017, Mission Hope Cancer Center accredited by the National Accreditation Program for Breast Cancer Centers (NAPBC) joined Dignity Health Central Coast hospitals. In Mission Hope’s cancer care program, breast cancer examination services and facility is expected to be provided to women. Moreover, in 2017, Dignity Health installed 3D imaging technology – Mammography in the central coast. This technology helps in detection of breast cancer before symptomatic stage, which increases 98% survival rate. Thus, this program is expected to create more awareness and early detection of cancer, which in turn is expected to augment the growth of women’s health diagnostic test market.
In 2016, Aeon Clinical Labs launched a RUO women’s health panel test, which is developed by Thermo Fischer Scientific. This test is based on PCR that detects 34 different target include candidiasis, bacterial vaginosis, and sexual transmitted diseases such as gonorrhea, chlamydia, and some others. Aeon is further aiming to expand genetic assays for pharmacogenomics and hereditary cancer in the near future.
Get Exclusive Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/971
According to National Cancer Institute (NCI), in 2016, around 22,280 women diagnosed with ovary cancer and around 14,240 women died due to ovary cancer in U.S. Furthermore, according to Cancer Research UK, in 2014, around 7,378 new cases of ovary cancer and around 55,222 cases of breast cancer were diagnosed in U.K. Moreover, around 20 cases of ovarian cancers are diagnosed every day and is projected to increase by 15% by 2035.
Some of the key players operating in the global women’s health diagnostic test market include Biomerieux SA, F. Hoffmann-LA Roche AG, Becton, Dickinson and Company, Siemens AG, Abbott Laboratories, Hologic, Inc., Koninklijke Philips N.V., Quest Diagnostics Inc., GE Healthcare, and Alere Inc.
Click To Continue Reading On Women’s Health Diagnostic Test Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]